Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Let's rehabilitate cognitive rehabilitation in multiple sclerosis.
Acute disseminated encephalomyelitis: an evaluation of 15 cases in childhood.
Enhancement of ventricular-subventricular zone-derived neurogenesis and oligodendrogenesis by erythropoietin and its derivatives.
Mortality following a brain tumour diagnosis in patients with multiple sclerosis.
Multiple sclerosis: potential risk factors in childhood and adolescence.
Do patient and proxy agree? Long-term changes in multiple sclerosis physical impact and walking ability on patient-reported outcome scales.
The Elderly Person With Multiple Sclerosis: Clinical Implications for the Increasing Life-Span.
Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis.
Functional course of Progressive Multifocal Leukoencephalopathy.
EDSS Change Relates to Physical HRQoL While Relapse Occurrence Relates to Overall HRQoL in Patients with Multiple Sclerosis Receiving Subcutaneous Interferon β -1a.
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases.
Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
Differential expression of glucose-metabolizing enzymes in multiple sclerosis lesions.
CD8(+) T-Cells as Immune Regulators of Multiple Sclerosis.
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.
Restriction genes for retroviruses influence the risk of multiple sclerosis.
TLR3 Agonist Poly-IC Induces IL-33 and Promotes Myelin Repair.
Alterations in Immune Cells and Mediators in the Brain: It's Not Always Neuroinflammation!
FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis.
Radiolabeled anti-aquaporin-4 protein antibody imaging: a valuable method for determining neuromyelitis optica.
Susceptibility Genes for Multiple Sclerosis Identified in a Gene-Based Genome-Wide Association Study.
Depression and hypomania symptoms are associated with high dose corticosteroids treatment for MS relapses.
The putative acceleration of optic neuritis when combined with chronic hepatitis B.
Repair and regeneration of lumbosacral nerve defects in rats with chitosan conduits containing bone marrow mesenchymal stem cells.
Pages
« first
‹ previous
…
698
699
700
701
702
703
704
705
706
…
next ›
last »